Cidara Therapeutics Inc (CDTX.OQ)
CDTX.OQ on NASDAQ Stock Exchange Global Market
4.40USD
4:00pm EDT
4.40USD
4:00pm EDT
Change (% chg)
$-0.05 (-1.12%)
$-0.05 (-1.12%)
Prev Close
$4.45
$4.45
Open
$4.40
$4.40
Day's High
$4.55
$4.55
Day's Low
$4.40
$4.40
Volume
15,146
15,146
Avg. Vol
25,906
25,906
52-wk High
$8.80
$8.80
52-wk Low
$3.65
$3.65
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Buy | -0.58 | December | 21 Aug 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 5 | 4 | 4 | 4 |
| (2) OUTPERFORM | 3 | 3 | 3 | 3 |
| (3) HOLD | 0 | 0 | 0 | 1 |
| (4) UNDERPERFORM | 0 | 0 | 0 | 0 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 1.38 | 1.43 | 1.43 | 1.62 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 4 | 0.00 | 0.00 | 0.00 | 0.38 |
| Quarter Ending Dec-18 | 4 | 0.00 | 0.00 | 0.00 | 0.38 |
| Year Ending Dec-18 | 4 | 0.00 | 0.00 | 0.00 | 0.88 |
| Year Ending Dec-19 | 7 | 0.00 | 0.00 | 0.00 | 0.92 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 5 | -0.58 | -0.56 | -0.60 | -0.89 |
| Quarter Ending Dec-18 | 5 | -0.60 | -0.58 | -0.64 | -0.84 |
| Year Ending Dec-18 | 5 | -2.96 | -2.70 | -3.16 | -3.34 |
| Year Ending Dec-19 | 7 | -2.37 | -1.94 | -3.20 | -3.01 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Jun-18 | 0.00 | 0.00 | 0.00 | 0.00 |
| Quarter Ending Mar-18 | 0.26 | 0.00 | 0.26 | 100.00 |
| Quarter Ending Dec-17 | 0.26 | 0.00 | 0.26 | 100.00 |
| Quarter Ending Sep-17 | 0.21 | 0.00 | 0.21 | 100.00 |
| Quarter Ending Jun-17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Earnings (per share) | ||||
| Quarter Ending Jun-18 | -0.66 | -1.13 | 0.47 | -70.77 |
| Quarter Ending Mar-18 | -0.64 | -0.80 | 0.16 | -24.22 |
| Quarter Ending Dec-17 | -0.76 | -0.69 | 0.07 | -9.37 |
| Quarter Ending Sep-17 | -0.94 | -0.73 | 0.21 | -22.52 |
| Quarter Ending Jun-17 | -0.88 | -0.99 | 0.11 | -12.32 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 |
| Quarter Ending Dec-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.38 |
| Year Ending Dec-18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.88 |
| Year Ending Dec-19 | 0.00 | 0.00 | 0.00 | 0.00 | 0.92 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | -0.58 | -0.60 | -0.65 | -0.65 | -0.89 |
| Quarter Ending Dec-18 | -0.60 | -0.63 | -0.67 | -0.67 | -0.84 |
| Year Ending Dec-18 | -2.96 | -2.96 | -2.82 | -2.82 | -3.34 |
| Year Ending Dec-19 | -2.37 | -2.37 | -2.64 | -2.64 | -3.01 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-18 | 0 | 0 | 0 | 0 |
| Quarter Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-18 | 0 | 0 | 0 | 0 |
| Year Ending Dec-19 | 0 | 0 | 0 | 0 |
| Earnings | ||||
| Quarter Ending Sep-18 | 0 | 0 | 2 | 2 |
| Quarter Ending Dec-18 | 0 | 0 | 2 | 2 |
| Year Ending Dec-18 | 0 | 0 | 1 | 3 |
| Year Ending Dec-19 | 0 | 0 | 2 | 2 |
Earnings vs. 
Estimates- BRIEF-Cidara Announces Stock And Warrants Offering Worth $120 Mln
- BRIEF-Cidara Therapeutics Files For Stock Shelf Of Up To $10 Mln
- BRIEF-Cidara Reports Q1 Loss Per Share $0.80
- BRIEF-Cidara Says Additional Data Confirm Positive Results In Antifungal Rezafungin
- BRIEF-Cidara Reports Positive Topline Results From Phase 2 Strive Trial Of Lead Antifungal Rezafungin